Skip to main content

COVID-19 clinical trials at UC Davis

5 research studies open to eligible people

Showing trials for
  • A Study of the Experimental PET/CT Radiotracer "18F-avb6-Binding-Peptide" After COVID-19 (Coronavirus) Infection

    open to eligible people ages 18 years and up

    This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.

    Sacramento, California

  • Cell therapy to Treat Patients with COVID-19

    open to eligible people ages 18 years and up

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    Sacramento, California and other locations

  • Experimental Treatment with Remdesivir for Patients Hospitalized With Coronavirus Infection (COVID-19)

    open to eligible people ages 18-99

    This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adults diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to approximately 100 sites globally. The study will compare different investigational therapeutic agents to a control arm. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, then this treatment may become the control arm for comparison(s) with new experimental treatment(s). Any such change would be accompanied by an updated sample size. Because background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized subjects. An independent Data and Safety Monitoring Board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. To evaluate the clinical efficacy, as assessed by time to recovery, of different investigational therapeutics as compared to the control arm.

    Sacramento, California and other locations

  • Outcomes Related to COVID-19 (Coronavirus) Treated with Hydroxychloroquine Among In-Patients with Symptomatic Disease

    open to eligible people ages 18 years and up

    ORCHID is a multicenter, blinded, placebo-controlled, randomized clinical trial evaluating hydroxychloroquine for the treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study personnel will all be blinded to study group assignment.

    Sacramento, California and other locations

  • Testing the Safety and Effectiveness of Experimental Sarilumab in Hospitalized Patients With COVID-19 (Coronavirus)

    open to eligible people ages 18 years and up

    Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata. Phase 3 Cohort 1: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline. Phase 3 Cohort 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.

    Sacramento, California and other locations